Nkarta (NKTX) EBT Margin (2019)
Nkarta (NKTX) posted quarterly EBT Margin of 1638637.4% for Q3 2019, up 879.95% quarter-over-quarter from 210093.89% in Q2 2019.
Nkarta (NKTX) EBT Margin (2019) Analysis & Trends
Nkarta's EBT Margin history runs 1 years deep, the most recent figure standing at 1638637.4% for Q3 2019.
- In Q3 2019, EBT Margin changed N/A year-over-year to 1638637.4%; the TTM figure through Dec 2020 stood at 13714285.71% (changed N/A YoY), while the FY2019 annual figure was 20461.74%, changed N/A from the prior year.
- EBT Margin for Q3 2019 stood at 1638637.4%, up from 210093.89% in the prior quarter.
- The five-year high for EBT Margin was 1638637.4% in Q3 2019, with the low at 210093.89% in Q2 2019.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBT Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.24 Bn | 131.39 Bn | 2.84 Bn | 41.75% |
| 2 | Regeneron Pharmaceuticals | 86.01 Bn | 78.02 Bn | 3.93 Bn | 35.61% |
| 3 | Argenx Se | 65.61 Bn | 60.42 Bn | 1.37 Bn | 35.71% |
| 4 | Moderna | 56.92 Bn | 51.78 Bn | 52.00 Mn | -528.97% |
| 5 | BeOne Medicines | 42.17 Bn | 37.07 Bn | 1.53 Bn | 18.33% |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.27 Bn | 992.69 Mn | 13.77% |
| 7 | BioNTech SE | 27.77 Bn | 9.38 Bn | 668.28 Mn | -25.06% |
| 8 | Insmed | 27.52 Bn | 26.36 Bn | 358.27 Mn | -2.67% |
| 9 | Royalty Pharma | 27.36 Bn | 26.52 Bn | - | 12.09% |
| 10 | Nkarta | 197.78 Mn | 197.78 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2019 | 1,638,637.40% |
| Jun 30, 2019 | -210,093.89% |